Key result
Among real-world UK patients with atrial fibrillation eligible for anticoagulation, 68% met inclusion criteria for RE-LY, 65% for ARISTOTLE, and 51% for ROCKET-AF based on CHA2DS2-VASc score.
Population
83,898 patients with atrial fibrillation in the United Kingdom identified in the General Practice Research…
Design
Cross-sectional
Authors
Loading...
UK AF patients align more with RE-LY/ARISTOTLE than ROCKET-AF criteria; leaves open generalizability of ROCKET-AF results to routine practice.
Cross-Sectional (n=83,898)
Patients enrolled in the RE-LY and ARISTOTLE trials were more reflective of the real-world UK atrial fibrillation population compared to those in ROCKET-AF, who represented a more narrowly defined, higher-risk group.
Lee et al. (2012) conducted a cross-sectional in Atrial fibrillation (n=83,898). Clinical trial eligibility criteria (RE-LY, ARISTOTLE, ROCKET-AF) vs. Real-world AF population was evaluated on Proportion of real-world patients with AF who met the inclusion/exclusion criteria for RE-LY, ARISTOTLE and ROCKET-AF. Among real-world UK patients with atrial fibrillation eligible for anticoagulation, 68% met inclusion criteria for RE-LY, 65% for ARISTOTLE, and 51% for ROCKET-AF based on CHA2DS2-VASc score.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: